profit from every $100 of sales.
$0$100
Kairos Pharma
$0.45-5.62% today
-42.7% in 1 year
1-year low $0.451-year high $4.80
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Kairos Pharma sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$5.45 million of profit last year.
SalesProfit
Kairos Pharma vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Kairos Pharma | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Kairos Pharma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -1 | -2 | -2 | -6 | |
| -0 | -2 | -2 | -5 | |
| -1 | -2 | -3 | -5 | |
| -0.10 | -0.16 | -0.23 | -0.30 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1 | 1 | 6 | 7 |
| Cash | 0 | 0 | 1 | 4 |
| Total debt | 1 | 1 | – | – |
| Total liabilities | 2 | 3 | 1 | 0 |
| -1 | -2 | 5 | 6 | |
| 11 | 11 | 11 | 18 | |
| – | – | -39.9% | -67.9% | |
| 89.1% | 87.2% | -54.5% | -85.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -0 | 0 | -4 | -3 | |
| – | – | – | – | |
| -0 | 0 | -4 | -3 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 0 | 0 | 0 | – |
Valuation
- –
- –
- –
- 1.6×
- –
- –
- –
- -224.1%
- -354.7%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -87.9%
- 87.0%
- -80.3%
- -83.3%
- -87.9%
- –
Growth
- –
- –
- +13.0%
- –
- +9.4%
Financial health
- -0.8×
- 0.00
- 0.0%
- –
- 27.07
- 27.07
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 952
Bottom 20%of 884
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.08 | -0.07 | −14.3% |
| Mar 31, 2026 | -0.07 | -0.02 | −275.3% |
| Nov 14, 2025 | -0.07 | -0.10 | +30.0% |
| Aug 12, 2025 | -0.08 | -0.06 | −33.3% |
| Apr 15, 2025 | -0.08 | -0.05 | −60.0% |
| Feb 26, 2025 | -0.09 | -0.06 | −43.8% |
| Nov 14, 2024 | -0.10 | -0.02 | −400.0% |
| Jun 30, 2024 | -0.02 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
48No pass
Benjamin Graham
64Pass
Philip Fisher
42No pass
Peter Lynch
62Pass
Joel Greenblatt
2No pass
Charlie Munger
45No pass
Terry Smith
40No pass
Questions about Kairos Pharma
Is Kairos Pharma a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Kairos Pharma AI analysis
What does Kairos Pharma do?
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It is in Biotechnology.
Does Kairos Pharma pay a dividend?
No. Kairos Pharma does not pay a dividend at the moment.
Is Kairos Pharma stock halal?
No. Kairos Pharma does not pass our halal screen: its cash and confirmed interest-bearing investments are 293% of its market value, at or above the 33% limit. How we check
How has Kairos Pharma stock done over the past year?
Down 42.7% over the past twelve months, to $0.45. It traded between $0.45 and $4.80 and is 90.5% below its high.
Who are Kairos Pharma's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Kairos Pharma's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.